

**Food and Drug Administration**

**Pre-Market Evaluation of Abuse-Deterrent Properties of Opioid Drug Products**

**Public Meeting**

**November 1, 2016 – Day 2: Development of Standardized In Vitro Testing to Evaluate Abuse Deterrence**

**Open Public Hearing on potential new approaches to abuse deterrence**

1. 11:00 AM	<b>Alexander Kraus, Grunenthal USA, Inc.</b>
2. 11:10 AM	<b>Nathan Langley, Gatekeeper Innovation, Inc.</b>
3. 11:20 AM	<b>Andrew Barrett, KemPharm, Inc.</b>

## Food and Drug Administration

### Pre-Market Evaluation of Abuse-Deterrent Properties of Opioid Drug Products

#### Public Meeting

#### November 1, 2016 – Day 2: Development of Standardized In Vitro Testing to Evaluate Abuse Deterrence

#### Open Public Hearing on standardized testing to evaluate abuse deterrence of opioid drug products

1. 1:00 PM	<b>Pamela Osborne</b>
2. 1:08 PM	<b>Sebastian Schwier, Grunenthal GmbH</b>
3. 1:16 PM	<b>Edwin Thompson, Pharmaceutical Manufacturing Research Services, Inc</b>
4. 1:24 PM	<b>Andrew Barrett, Kem Pharm, Inc.</b>
5. 1:32 PM	<b>Ravi Harapanhalli, Amneal Pharmaceuticals</b>
6. 1:40 PM	<b>Candis Edwards, Amneal Pharmaceuticals</b>
7. 1:48 PM	<b>Edward Cone, PinneyAssociates</b>
8. 1:56 PM	<b>Robert Bianchi, Prescription Drug Research Center</b>
9. 2:04 PM	<b>Beatrice Setnik, INC Research</b>